<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01483872</url>
  </required_header>
  <id_info>
    <org_study_id>101094</org_study_id>
    <nct_id>NCT01483872</nct_id>
  </id_info>
  <brief_title>Use of a Novel Catheter Lock Solution For Treatment of Hemodialysis Catheter Infections</brief_title>
  <official_title>Phase II Trial of a Novel Catheter Lock Solution For Adjunctive Treatment of Hemodialysis Catheter-Associated Bacteremia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: To conduct a randomized, double-blinded, controlled phase II trial to investigate the
      use of a catheter lock solution consisting of N-acetylcysteine, tigecycline and heparin, in
      addition to systemic antibiotics, for the treatment of hemodialysis catheter-associated
      bacteremia via a catheter-salvage strategy.

      The investigators plan to randomize 102 patients with hemodialysis catheter-associated
      bacteremia to one of two treatment arms. All patients will receive systemic antibiotics for
      treatment of their infection. Additionally, patients randomized to the interventional arm
      will also receive a catheter lock solution consisting of N-acetylcysteine, tigecycline and
      heparin for 2 weeks with the aim of salvaging the catheter. The control arm will receive only
      an anticoagulant solution as a catheter lock which is standard of care - this can be either
      heparin or citrate (depending on what agent is standard of care for a particular patient).
      The main outcome of interest is successful treatment which is defined as a resolution of the
      current episode of bacteremia as well as lack of recurrent bacteremia within 90 days of
      follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was stopped due to poor enrollment.
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success Rate</measure>
    <time_frame>90 days</time_frame>
    <description>Nine participants signed consent forms, only one randomized. Data was not analyzed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Infection; Dialysis Catheter</condition>
  <arm_group>
    <arm_group_label>NAC/Tigecycline/Heparin combination lock solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A combination of the above three drugs will form the catheter lock solution that will be instilled into the catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard anticoagulant (heparin or citrate)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard anticoagulant (heparin or citrate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NAC/Tigecycline/Heparin combination lock solution</intervention_name>
    <arm_group_label>NAC/Tigecycline/Heparin combination lock solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard anticoagulant (Heparin or Citrate)</intervention_name>
    <arm_group_label>Standard anticoagulant (heparin or citrate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any adult (â‰¥ 18 years of age) who has ESRD and a prevalent or incident tunneled
             hemodialysis catheter and expected to continue hemodialysis for 3 months will be
             eligible for enrollment.

        Exclusion Criteria:

          -  The following patients will be excluded from study entry:

               1. patient is unable (and no guardian or legal representative is available) or
                  unwilling to provide informed consent and

               2. patient is allergic to NAC, tigecycline, minocycline, or heparin.

        The following patients will be excluded from randomization:

          1. patient has evidence of a complicated bacteremia such as endocarditis, septic
             thrombophlebitis, septic emboli, osteomyelitis, deep seated abscess, or hypotension
             requiring use of vasopressors,

          2. patient has evidence of an exit site infection around the catheter such as a pus
             pocket, purulent drainage, or erythema,

          3. patient is pregnant or will become pregnant,

          4. the infection is due to an organism that is resistant to tigecycline such as Candida
             or Pseudomonas species.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 26, 2011</study_first_submitted>
  <study_first_submitted_qc>November 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2011</study_first_posted>
  <results_first_submitted>August 15, 2019</results_first_submitted>
  <results_first_submitted_qc>August 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2019</results_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Saima Aslam</investigator_full_name>
    <investigator_title>Asst Adjunct Prof</investigator_title>
  </responsible_party>
  <keyword>salvage infected hemodialysis catheters</keyword>
  <keyword>novel catheter lock solution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tigecycline</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>9 patients signed consent forms. Only one developed an active infection and thus underwent randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NAC/Tigecycline/Heparin Combination Lock Solution</title>
          <description>A combination of the above three drugs will form the catheter lock solution that will be instilled into the catheter
NAC/Tigecycline/Heparin combination lock solution</description>
        </group>
        <group group_id="P2">
          <title>Standard Anticoagulant (Heparin or Citrate)</title>
          <description>Standard anticoagulant (heparin or citrate)
Standard anticoagulant (Heparin or Citrate)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Success Rate</title>
        <description>Nine participants signed consent forms, only one randomized. Data was not analyzed.</description>
        <time_frame>90 days</time_frame>
        <population>Nine participants signed consent forms, only one randomized. Data was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Nine participants signed consent forms, only one randomized. Data was not analyzed.</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate</title>
          <description>Nine participants signed consent forms, only one randomized. Data was not analyzed.</description>
          <population>Nine participants signed consent forms, only one randomized. Data was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>Nine participants signed consent forms, only one randomized. Data was not analyzed.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Nine participants signed consent forms, only one randomized. Study terminated due to low enrollment. Data was not analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Saima Aslam</name_or_title>
      <organization>UCSD</organization>
      <phone>858 657 7463</phone>
      <email>saslam@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

